// App-Quantinova.ai

205 : Fractionated dose radiolabeled anti−prostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu−J591) for progressive metastatic castration−resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Jaspreet S. Batra

Principal Investigators

  • Beerinder S. Karir

  • Kavya Pinto-Chengot

  • Yuliya Jhanwar

  • Shankar Vallabhajosula

  • Paul J. Christos

  • Gillian Hodes

  • Linda Lam

  • Ana M. Molina

  • Himisha Beltran

  • David M. Nanus

  • Stanley J. Goldsmith

  • Neil Harrison Bander

  • Scott T. Tagawa

Medical Centers

  • Weill Cornell Medical College, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

  • Folate Hydrolase 1

Drug/Treatment

  • J591

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00538668

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved